Literature DB >> 15385936

AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity.

I S Lossos1, R Levy, A A Alizadeh.   

Abstract

Activation-induced cytidine deaminase (AID), highly expressed in germinal center (GC)-lymphocytes, is involved in somatic hypermutation (SHM). We examined AID expression in diffuse large B-cell lymphomas (DLBCL) of germinal center B-cell (GCB)-like and activated B-cell (ABC)-like subtypes. These two types of DLBCL are characterized by high and low expression of GC-specific genes, respectively. AID expression was detected in both GCB- and ABC-like DLBCL, thus demonstrating a dissociation between AID expression and that of other GC genes. We also tested for the presence of intraclonal heterogeneity in immunoglobulin and BCL6 genes in those same tumors and in follicle center lymphomas (FCL) that transformed to DLBCL. The level of AID expression did not correlate with the presence of intraclonal sequence heterogeneity in either IgV(H) or BCL6. Our findings suggest that lymphomas maintain some but not all of the gene expression signatures of their normal B-cell counterparts. The fact that AID expression can be elevated without intraclonal sequence heterogeneity raises the possibility that other factors are required for SHM in these tumors. We found decreased levels of AID expression in DLBCL that evolved from FCL and which had acquired new mutations in their BCL6 genes. This dissociation suggests that AID expression and SHM may occur at the time prior to the clinical detection of transformed lymphoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385936     DOI: 10.1038/sj.leu.2403488

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  25 in total

1.  Genomic uracil homeostasis during normal B cell maturation and loss of this balance during B cell cancer development.

Authors:  Sophia Shalhout; Dania Haddad; Angela Sosin; Thomas C Holland; Ayad Al-Katib; Alberto Martin; Ashok S Bhagwat
Journal:  Mol Cell Biol       Date:  2014-08-25       Impact factor: 4.272

2.  Ancient phylogenetic beginnings of immunoglobulin hypermutation.

Authors:  Jaroslav Kubrycht; Karel Sigler; Michal Růzicka; Pavel Soucek; Jirí Borecký; Petr Jezek
Journal:  J Mol Evol       Date:  2006-10-06       Impact factor: 2.395

Review 3.  The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond.

Authors:  Kazuo Kinoshita; Taichiro Nonaka
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

4.  PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Authors:  Marién Pascual; María Mena-Varas; Eloy Francisco Robles; Maria-Jose Garcia-Barchino; Carlos Panizo; Sandra Hervas-Stubbs; Diego Alignani; Ainara Sagardoy; Jose Ignacio Martinez-Ferrandis; Karen L Bunting; Stephen Meier; Xavier Sagaert; Davide Bagnara; Elizabeth Guruceaga; Oscar Blanco; Jon Celay; Alvaro Martínez-Baztan; Noelia Casares; Juan José Lasarte; Thomas MacCarthy; Ari Melnick; Jose Angel Martinez-Climent; Sergio Roa
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

5.  Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures.

Authors:  Ileana S Mauldin; Adela Mahmutovic; Samuel J Young; Craig L Slingluff
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases.

Authors:  Sachini U Siriwardena; Kang Chen; Ashok S Bhagwat
Journal:  Chem Rev       Date:  2016-09-01       Impact factor: 60.622

7.  BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Authors:  Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

8.  Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.

Authors:  Kiyoko Kawamura; Akihiko Wada; Ji-Yang Wang; Quanhai Li; Akihiro Ishii; Hideki Tsujimura; Toshiyuki Takagi; Makiko Itami; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-16       Impact factor: 4.553

9.  Activation induced cytidine deaminase expression in lymphocyte predominant Hodgkin lymphoma.

Authors:  A Mottok; M-L Hansmann; A Bräuninger
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

10.  AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.

Authors:  J Jiao; Y Jin; M Zheng; H Zhang; M Yuan; Z Lv; W Odhiambo; X Yu; P Zhang; C Li; Y Ma; Y Ji
Journal:  Clin Exp Immunol       Date:  2018-11-13       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.